Published in Med Sci Monit on September 09, 2016
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet (2004) 2.55
Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem (2001) 2.08
DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet (1998) 1.94
Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation (2007) 1.70
Genetic contributions to plasma total antioxidant activity. Arterioscler Thromb Vasc Biol (2001) 1.61
The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei) (2002) 1.41
Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem (2006) 1.32
Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol (2003) 1.31
Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid Redox Signal (2010) 1.21
Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis (2000) 1.12
Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet (2002) 1.10
Genomic approaches to coronary artery disease. Indian J Med Res (2010) 0.96
Gene-environment interaction and oxidative stress in cardiovascular disease. Atherosclerosis (2008) 0.94
The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology (2009) 0.93
Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest (2004) 0.91
Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem (2001) 0.90
Gene-smoking interactions in multiple Rho-GTPase pathway genes in an early-onset coronary artery disease cohort. Hum Genet (2013) 0.88
PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol (2004) 0.87
p53 codon 72 polymorphism and coronary artery disease: evidence of interaction with ACP₁. Med Sci Monit (2012) 0.85
Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab (2002) 0.84
Low frequency haplotypes of E-selectin polymorphisms G2692A and C1901T give increased protection from coronary artery disease. Med Sci Monit (2011) 0.83
Evaluation of polymorphisms in paraoxonase 2 (PON2) gene and their association with cardiovascular-renal disease risk in Mexican Americans. Kidney Blood Press Res (2009) 0.82
Association of cys 311 ser polymorphism of paraoxonase-2 gene with the risk of coronary artery disease. Arch Iran Med (2008) 0.81
The Cys(311)Ser polymorphism of paraoxonase 2 (PON2) is associated with albumin-to-creatinine ratio (ACR) in Mexican Americans. Nephrol Dial Transplant (2007) 0.81
Associations between genetic polymorphisms of paraoxonase genes and coronary artery disease in a Taiwanese population. Clin Biochem (2013) 0.78